02157 LEPU BIO-B
- 2.850
- +0.020+0.71%
LEPU BIO-B News
One Lepu Biopharma Insider Has Reduced Their Stake
Why We're Not Concerned Yet About Lepu Biopharma Co., Ltd.'s (HKG:2157) 26% Share Price Plunge
Changes in Hong Kong stocks | Lepu Bio-B (02157) is now up more than 8%. The company has released a number of research results and recently raised funds for ADC candidate product development
Lepu Bio-B (02157) is now up more than 8%. As of press release, it has risen 7.83% to HK$4.82, with a turnover of HK$28.239,500.
Lepu Bio-B (02157.HK) successfully placed 51.17 million shares to raise HK$230 million
On May 24, GLONGHUI | Lepu Bio-B (02157.HK) announced that all conditions of the placement matters contained in the placement agreement (including (including) approval by the Listing Committee for the listing and trading of the placement shares) have been met, and that the placement was completed on May 24, 2024. The company has successfully placed a total of 51.17 million shares at the placement price of HK$4.58 per share to no less than six undertakers, accounting for about 3.09% and 2.99% of all issued H shares and all issued shares after the expansion of the allotted shares issued and issued, respectively. Total proceeds from placement transactions and proceeds
Lepu Biopharma to Present Three Studies During US Cancer Meet; Shares Dip 7%
Changes in Hong Kong stocks | Lepu Bio-B (02157) fell more than 12% from the monthly high point and already fell 35% to raise HK$230 million in the proposed discounted placement of shares
Lepu Bio-B (02157) fell more than 12% in the intraday period, to a low of HK$4.23. It is already 35% lower than the monthly high of HK$6.5. As of press release, it decreased by 7.52% to HK$4.55, with a turnover of HK$357.44,300.
Lepu Bio-B (02157.HK): Results of three clinical studies were announced at the 2024 ASCO Annual Meeting
On May 24, GLONGHUI (02157.HK) announced the results of three clinical studies of the company's innovative drug candidates and combination therapies (including antibody drug conjugates (“ADC”) MRG004A, MRG003 and HX008, and combination therapy with HX008 and Nirapali at the 2024 American Society of Clinical Oncology (“ASCO”) annual meeting.
Lepu Biopharma Targets Up to HK$230 MIllion in Share Placement; Shares Fall 5%
[Hong Kong Stock Connect] Lepu Biotech (02157) falls 5.5% and plans to discount 13.09% of the allotment of shares to raise HK$230 million net
Jinwu Financial News | Lepu Biotech (02157) traded shares at a discounted price and fell in response. As of press release, it reported HK$4.98, down 5.5%, with a turnover of HK$31.21,000. According to the announcement, on May 17, 2024, the company (as issuer) entered into a placement agreement with the placement agent (CITIC Securities and HSBC). According to this, it is intended to allocate a maximum of 51.17 million H shares to no less than six independent undertakers, accounting for approximately 3.09% and 2.99% of the expanded H shares and the total issued share capital, respectively. The placement price per share was HK$4.58, a 13.09% discount on the closing price of HK$5.27 on the previous trading day. Allocate
Lepu Bio-B (02157.HK) plans to place up to 51.17 million shares to raise a total of HK$234 million
Gelonghui, May 17, 丨 Lepu Bio-B (02157.HK) announced that on May 17, 2024, the company (as issuer) entered into a placement agreement with the placement agent (CITIC Securities and HSBC). According to this, the placement agent conditionally agreed to act as the company's agent to place up to 51.17 million shares at the placement price of HK$4.58 per H share. Placed shares accounted for about 3.19% and 3.08% of the company's total issued H shares and all existing issued share capital as at the date of this announcement; they also each accounted for the company's financial allocations
Lepu Biopharma Co., Ltd.'s (HKG:2157) 58% Share Price Surge Not Quite Adding Up
LEPU BIO-B: 2023 Annual Report
Changes in Hong Kong stocks | Lepu Bio-B (02157) rose more than 7% to complete clinical trial of a drug to treat advanced solid tumors
Lepu Bio-B (02157) rose more than 7%, rising by about 45% during the month. As of press release, it rose 5.95% to HK$4.63, with a turnover of HK$14.9943 million.
Is Lepu Biopharma (HKG:2157) A Risky Investment?
Lepu Bio-B (02157.HK): Recent developments in the licensing agreement with ASTRAZENECA for CMG901
Lepu Bio-B (02157.HK) announced the latest status of the exclusive global license agreement between KYM Biosciences Inc. (“KYM”, a joint venture formed by the Company and Connoya Biomedical Technology Co., Ltd. (“Connoya”) and AstraZeneca AB (“AstraZeneca”, a global pharmaceutical company) for the development and commercialization of CMG901 (a drug candidate developed jointly by the company and Connoya through KYM).
Changes in Hong Kong stocks | Lepu Bio-B (02157) rose more than 5%, commercialization achieved a breakthrough, and revenue soared 1347% last year
Lepu Bio-B (02157) rose more than 5%. As of press release, it rose 5.95% to HK$3.56, with a turnover of HK$3.336,800.
Looking at the increase in value of Lepu Bio-B (2157.HK) from an annual report that “combines speed and quality”
In 2023, due to the combined effects of macroeconomic factors such as global economic fluctuations, capital market performance was not ideal. In particular, the innovative drug sector of Hong Kong stocks continued to fluctuate and adjust. The market further released pessimistic values, and sector valuations also fell to a historically low range for a while. At the same time, the domestic healthcare industry's financing environment has also been significantly affected. According to the Sino-Thai International Research Report, the total financing of the domestic healthcare industry fell 30.1% year on year to 10.9 billion US dollars in 2023, equivalent to about 1/3 of 2021 and falling back to around 2017. Pan Tianqi of the League of Nations Foundation believes that the present is just what is expected
Breakthrough in business development and commercialization, Lepu Bio-B (02157)'s revenue in 2023 soared 1347% to 225 million yuan
Lepu Bio-B (02157) disclosed the 2023 annual results announcement. The group achieved revenue of 2.25 during the reporting period...
LEPU BIO-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31, 2023
Lepu Bio-B (02157.HK) held a board meeting on March 27 to consider and approve annual results
Glonghui March 15 | Lepu Bio-B (02157.HK) announced that the board of directors meeting will be held on March 27, 2024 (Wednesday) to consider and approve (among other things) the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, consider recommending payment of a final dividend (if any), and deal with other matters.
Analysis
Price Target
No Data
